hide
Free keywords:
-
Abstract:
Due to its annual death rate and the potential to cause pandemics, Influenza remains a major public health concern. Efforts to control the annual spread of influenza have centered on prophylactic vaccinations. Influenza viruses for human vaccine production are currently grown on embryonated eggs. However, this production process conveys major drawbacks such as lack of scalability, inability of some strains to replicate on eggs to high enough yields, and possible allergic reactions induced by egg proteins. These limitations emphasize the need for an alternative process. In recent years several continuous cell lines such as the Madin-Darby canine kidney (MDCK) have been successfully established for the production of influenza vaccines. These processes require the modification of existing downstream strategies to account for the modified upstream technology.
The presented study focuses on the development of two downstream processing schemes for the purification of human Influenza A/PR/8/34 (H1N1) virus. Purification scheme 1 is based on a combination of size exclusion and anion exchange chromatography. Scheme 2 is centered on a lectin affinity chromatography. Both downstream processes represent a promising tool for the effective processing of MDCK-cell derived vaccines. In addition, the glycan analysis provides a powerful tool for the quality control of cell and egg derived antigens.
